1. The Global Leader in Genetic Science for Eye Care

2. DNA Testing for Eye Care The Problem Today Full DNA sequencing is too costly, has a slow turn-around, delivers too much data, and lacks accuracy The Avellino Solution Available Today Targeted DNA Testing for Eye Care –Simple, cheek swab –Rapid, 24-48 hours –Affordable –Accurate, no false positives or negatives –Actionable, “go/no-go” surgery decision

3. Our Growth Strategy Build on our DNA Test Platform Business Diagnostic Testing Pharmacogenomics Gene Therapy 2015 Global Genomics Market–$17B in 2020 $11B in 2025, CAGR 48.9%

4. Large Market Opportunities Exist for our Technology in Eye Care LASIK 2-3 M worldwide 350,000 United States 2015 Glaucoma 60 M worldwide 3 M United States Retina - AMD 150-200 M worldwide 2-5 M United States Cataract 20-30 M worldwide 3 M US

5. Avellino DNA Test Development Roadmap Moving over time from the front to the back of the eye Corneal Dystrophy Refractive Keratoconus EBMD Cataract Corneal Dystrophy Keratoconus EBMD Retina Glaucoma Pharmacotherapy Retinits Pigmentosa Macular Degeneration Our market today Active R&D Back of the Eye Ideas on the Drawing Board

6. Avellino Labs Technology Advantage Clinical Data Half Million and Counting Int’l Patent Protection 4 Granted, 3 Pending/Provisional Standard of Care Japan and South Korea 500+ Protected Global Lab Network 9 Labs Worldwide CLIA Certified in US Collaborative R&D California, South Korea & China

7. Intellectual Property Portfolio US and International Patents Issued 1.System For Diagnosis Of Avellino Corneal Dystrophy 1.Method For Requesting And Checking Results Of Diagnostic Tests For Avellino Corneal Dystrophy 1.Primer For Detecting Avellino Corneal Dystrophy 1.Multi-Spot Metal-Capped Nanostructure Array Nucleic Acid Chip For Diagnosis Of Corneal Dystrophy And Preparing Method Thereof US and International Pending Patents 1.Methods For Improved Isolation Of Genomic DNA Templates For Allele Detection Pct/Us14/29466 2.Methods For Multiplex Detection Of Alleles Associated With Ophthalmic Conditions Pct/Us14/65975 3.Gene Therapy – Methods for the Treatment of Corneal Dystrophies US Provisional 62/242,204

8. Competition Unique Positioning –The only company dedicated to Genetic Science in Eye Care Competitive Strategy –Exclusive focus on the ophthalmic market –Rapid first-to-market products –Invest in IP to erect high barriers to entry –24/7 rapid research via global lab collaboration to stay ahead Competitive Landscape –Larger players are focused on large opportunities outside eye care i.e. Breast Cancer & Alzheimer's

9. Management Team Gene Lee, Chairman and Founder Started Avellino Labs in 2008 in South Korea Serial Entrepreneur 20 years in Pharma & Healthcare Peter Falzon, CEO Joined Avellino Labs in 2015 Public & Private Company CEO Experience 25 years in the Eye Care Industry Scott Korney, COO Established Avellino Lab USA in 2012 Entrepreneur and Founder Experience 30 years in the Bio-Science Industry

10. Scientific Advisory Board Anthony J. Aldave, MD UCLA, Jules Stein Eye Institute Chief of the Cornea and Uveitis Division Sonia Yoo, MD University of Miami, Bascom Palmer Eye Institute Professor of Ophthalmology and Chief of LASIK Services Ed Manche, MD Stanford University, Byers Stein Eye Institute Chief of Cornea and Refractive Surgery Janey Wiggs, MD, PhD Harvard University, Massachusetts Eye and Ear Infirmary Associate Director, Ocular Genomics Institute Terry Kim, MD Duke University Eye Center Chief of Cornea and External Disease Services

11. Proprietary and Confidential Anthony J. Aldave, MD UCLA, United States John Marshall PhD King’s College, UK Francesco Carones, MD Private Practice, Italy Burkhard Dick, MD Bochum University, Germany International Medical Advisory Board Wang Qinmei, MD Wenzhou Univ, China Zhou Xingtao, MD Fudan Univ, China Zhang Fenju, MD Beijing Tongren Hosp, China

12. Company Milestones